2nd Quarter - Report

W STRATEGIES, LLC for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

HHS rule related to expedited coverage of innovative technology.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States

Taxation/Internal Revenue Code TAX

H.R. 184: Protect Medical Innovation Act. H.R.1645: Fostering Innovation Act of 2017.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States

Bills named: H.R. 184 (115th), H.R. 1645 (115th)

Health Issues HCR

Promoted life sciences community and communicated economic and health benefits of the industry. H.R.1628: American Health Care Act. H.R.2430/S.934: FDA Reauthorization Act of 2017. Education about the value of innovative new medicines. H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES

Bills named: H.R. 849 (115th), H.J.Res. 51 (115th), S. 934 (115th), H.R. 2430 (115th), H.R. 1628 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.